Indian Pharmaceutical Exports to U.S. Declined
India experienced a nearly 10 percent drop in pharmaceutical exports to the United States last year.
Updated on Sept. 18, 2026 in Healthcare
Live Poll
Is diversifying export markets away from a single dominant partner beneficial for national economic stability?
India's pharmaceutical shipments to the United States fell from USD 10.5 billion to USD 9.5 billion last year. This decline represents a total export erosion of nearly USD 1 billion.
Why it matters
The country is actively diversifying its export footprint to reduce a heavy reliance on the U.S., which historically accounted for 35 percent of its total pharmaceutical sales. By pivoting toward new markets, India aims to stabilize its pharmaceutical sector against specific regional volatility.
Total Indian pharmaceutical exports reached USD 8.1 billion during the April-June 2026 quarter, marking a 6.8 percent growth compared to the same period in 2025. The shift away from the U.S. market resulted in an export value drop to USD 9.5 billion.
The players
Pharmexcil
The Pharmaceuticals Export Promotion Council of India acts as the primary government-affiliated agency responsible for promoting the nation's pharmaceutical exports globally.
The details
To mitigate the impact of reduced demand in the U.S., India is intensifying its promotional efforts in Brazil, Latin America, Africa, and Europe. Furthermore, the nation is consolidating its industry outreach by unifying pharmaceutical and medical device exhibitions under the Bharat Health Global Expo banner.
Timeline
Last year: India saw a near 10 percent decline in pharmaceutical exports to the U.S.
April-June 2026: Total pharmaceutical exports grew 6.8 percent compared to the prior year.
2027: The second edition of the Bharat Health Global Expo is currently being planned.
Market Landscape
India's strategic pivot reflects a broader shift toward market diversification to move away from the historical 35 percent U.S. market share dependence. This transition positions the Indian pharmaceutical industry to build greater resilience by spreading its supply chain across emerging regions.
For international healthcare providers and distributors, this shift may signal changes in the availability and pricing of pharmaceutical products originating from India. Buyers should monitor potential supply route adjustments as the industry pivots its focus toward new markets in Africa and Latin America.
The takeaway
India is successfully offsetting losses in the U.S. market through growth in other regions, demonstrating a resilient shift in global trade strategy. Readers should anticipate that Indian pharmaceutical firms will continue prioritizing these newer markets to ensure long-term stability.
What happens next
The second edition of the Bharat Health Global Expo is planned for 2027.
Further reading
Learn more about shifting global medical supply chain trends in our Healthcare section.
Live Poll
Is diversifying export markets away from a single dominant partner beneficial for national economic stability?
